Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Key Points

• Increased Overall Response Rates were noted in the tumor center and invasive margin, affecting prognosis.
• The risk analysis in the Maintenance set identified key differences based on treatment arm and tumor location.
• Observational analysis of treatment impacts on immune microenvironment highlights potential predictive biomarkers.
• Findings suggest implications for personalized therapies in patients with RAS wt metastatic CRC through immune microenvironment assessment.